Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Observational 1Interventional 1

Sponsor

Conditions

Myasthenia Gravis 2

Interventions

pembrolizumab 164Carboplatin 136Cisplatin 84Paclitaxel 80Gemcitabine 77Pemetrexed 74Bevacizumab 65Docetaxel 54Fluorouracil 50Oxaliplatin 48Dexamethasone 45durvalumab 42atezolizumab 40Leucovorin 40130-nm albumin-bound paclitaxel 40Capecitabine 38Nivolumab 35Cetuximab 35Rituximab 33Cyclophosphamide 33Injections 31Fulvestrant 30venetoclax 28Prednisone 28Lenalidomide 27enzalutamide 26Irinotecan 25pomalidomide 24Letrozole 24daratumumab 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × ravulizumab × 30 days × Clear all
NCT07596784 2026-05-19

Efficacy and Safety of Ravulizumab in Chinese Adults Participants With Generalized Myasthenia Gravis (gMG)

Alexion Pharmaceuticals, Inc.

Phase 3 Not yet recruiting
20 enrolled

Myasthenia Gravis

NCT06909253 2026-05-15

MG-ARCADIA

AstraZeneca

Recruiting
50 enrolled

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡